Biomarker analysis report

2017-08-29

Contents

1	The dataset	1
2	Representativeness: Selection Bias of Biomarker Population 2.1 Check selection bias in terms of key clinical variables, between full population and BEP 2.2 Check whether the clinical outcome in BEP is comparable to the full population 2.3 Examine whether the prognostic/null trend of key clinical variables holds in BEP	2
3	Biomarker property and its association to clinical variables 3.1 Biomarker property and relationship to clinical variable	10 11
4	Biomarker cutoff exploration/selection 4.1 Try different cutoffs - look for consistent trend	11 11
5	Biomarker subgroup analysis (using selected cutoff) 5.1 Estimations within each subgroup	13

1 The dataset

The dataset have 368 entries. In which 309 are in biomarker evaluable population (BEP).

Endpoint of interest: ResponseBiomarker: KRAS.exprsBiomarker type: numeric

2 Representativeness: Selection Bias of Biomarker Population

In this section, we are trying to answer the question: Are biomarker evaluable population representative of the full population population?

Key baseline demographics and prognostic characteristics (including stratification variables and any variables with known prognostic effect) and efficacy outcomes should be summarized by treatment groups and compared between biomarker evaluable population (BEP) and the full population. These analyses are conducted to investigate any potential selection bias associated with the availability of the biomarker (e.g. we may not get enough tissue for patients whose tumor size is small. Therefore they may be excluded from BEP).

The key clinical biomarkers considered are:

clinical.vars.class

Sex Age
"categorical" "numeric"


2.1 Check selection bias in terms of key clinical variables, between full population and BEP

	All	BEP
Sex		
Total	368	309
NA's	0	0
F	184 (50%)	147 (47.57%)
M	184 (50%)	162 (52.43%)
Age		
N	368	309
Mean	54.03	54.29
Median	54	54
Min-Max	3089	3089
NA's	0	0

2.2 Check whether the clinical outcome in BEP is comparable to the full population

The following plot compares response outcome in BEP vs. the full population. The response category distribution is plotted for each arm. The BEP bars are expected to be comparable to those in full population.

```
Rsp.out <- PlotRspBar(data=input, outcome.var=outcome.var, binary=FALSE,
rsp.levels=rsp.levels, trt=trt, bep.indicator=BEP.indicator,
compare.bep.itt=TRUE, bep = BEP)</pre>
```



kable(Rsp.out\$count,caption="count")

Table 2: count

	CR	PR	SD	NON CR/PD	PD	NE
Full:All	6	90	145	49	74	1
BEP:All	5	80	122	40	61	0


kable(round(Rsp.out\$perc,2), caption="percentage")

Table 3: percentage

	CR	PR	SD	NON CR/PD	PD	NE
Full:All BEP:All			-	00	0.2	

Summarize the response in two classes - rsp vs. non-rsp:

```
Rsp.out.2 <- PlotRspBar(data=input, outcome.var=outcome.var, binary=TRUE,
rsp.response = rsp.response,
rsp.nonresponse = rsp.nonresponse,rsp.name=rsp.name, trt=trt, bep.indicator=BEP.indicator,
compare.bep.itt=TRUE, bep = BEP)</pre>
```



kable(Rsp.out.2\$count,caption="count")

Table 4: count

rsp	non-rsp
96	269
85	223
	96

kable(round(Rsp.out.2\$perc,2), caption="percentage")


Table 5: percentage

	rsp	non-rsp
Full:All	0.26	0.74
BEP:All	0.28	0.72

2.3 Examine whether the prognostic/null trend of key clinical variables holds in BEP


The following forest plot can be used to examine whether any of the key prognostic clinical variables still show prognostic trend in BEP:

entries with missing outcome.var are removed! 365 entries left
entries with missing outcome.var are removed! 308 entries left




entries with missing outcome.var are removed! 365 entries left


In BEP, Grouped by Sex



entries with missing outcome.var are removed! 308 entries left







3 Biomarker property and its association to clinical variables

Before performing cutoff exploraotry analysis, it is important to check a biomarker's property. For example, whether this biomarker has a bi-modal or multi modal distribution - if so, this biomarker may has natural cutoff.

Relationship between the biomarker and key demographic and prognostic variables should also be investigated using bivariate plots. Prognostic property of the biomarker should also be assessed, by estimates of the clinical efficacy in the control arm.

3.1 Biomarker property and relationship to clinical variable

The following results show single variate plot for biomaker and bi-variate plots to investigate biomarker-clinical variable relationship.

```
PlotProperty(data=input, biomarker.var=bm, biomarker.class=bm.class,
                  var=clinical.vars,
                  var.class=clinical.vars.class,
                  log2=FALSE, par.param = list(mfrow=c(2,3)))
             Distribution of KRAS.exprs
                                                                                                     KRAS.exprs by Age
                   N = 309
  0000
                                             1500
                                                                                        200
  0.004
                                             1000
                                                                                        1000
  0.003
                                                                                     KRAS.exprs
  200
                                             500
                                                                                        200
  0 001
```

4 Biomarker cutoff exploration/selection

1000

KRAS.exprs

500

1500

Results in this section could be used to examine multiple candidate cutoffs for a continuous biomarker. The need for cut-off determination should be rooted in the development strategy. In general, an exhaustive search looking at all possible cut-off values is not recommended for decision making. Over-optimized cutoff using one set of clinical data may lead to hard-to-reproduce results. When determining a cutoff, biomarker property should be considered - e.g. cut at a low-dense point may be more robust to population shift. The cutoff selection should also fit the program's stratigitic considerations. There is always a prevalence-effect size trade-off, inputs from multiple functions are needed - for example whether the team is willing to take more risk in PTS (high prevalence, weaker signal) or the team is willing to target at smaller population (lower prevalence, stronger signal)

4.1 Try different cutoffs - look for consistent trend

The following figures investigate whether the biomarker shows a within-arm effect (e.g. patients with higher biomarker value tend to have better clinical outcome):

```
show.itt=TRUE, show.bep=TRUE,
covariate=covariate, strata=strata)
```

```
## Covariate adjustment and stratification are not supported for binary outcome
## Some NAs in var column, will define the non NA entries as BEP
## only 1 arm; show.itt is set to FALSE
## only 1 arm; show.bep is set to FALSE
```

Within-arm Effect of Biomarker Response, KRAS.exprs Unadjusted, unstratified analysis

Subgroup	Group	nRsp/N	Rsp Rate	deltaRR	(CI)	raw P				
KRAS.exprs(>=25%, 25.28)	Less	21 / 77	0.27		-			_		
	Greater	64 / 232	0.28	0	(-0.11 - 0.12)	1		-		
KRAS.exprs(>=50%, 72)	Less	35 / 153	0.23							
	Greater	50 / 156	0.32	0.09	(-0.01 - 0.2)	0.093		+	-	-
KRAS.exprs(>=75%, 182.28)	Less	56 / 231	0.24							
	Greater	29 / 78	0.37	0.13	(0 - 0.26)	0.039			-	
KRAS.exprs(<25%, 25.28)	Greater	64 / 232	0.28			= = =				
	Less	21 / 77	0.27	0	(-0.12 - 0.11)	1		_		
KRAS.exprs(<50%, 72)	Greater	50 / 156	0.32							
	Less	35 / 153	0.23	-0.09	(-0.2 - 0.01)	0.093	-			
KRAS.exprs(<75%, 182.28)	Greater	29 / 78	0.37							
	Less	56 / 231	0.24	-0.13	(-0.26 - 0)	0.039	-			
							ı	-	1	
						-0.26	-0.13	0 deltaRR	0.13	0.26

The forest plots above show within-arm response rate difference (delta) between biomarker high (>= cutoff) vs. low (< cutoff) group. For a given arm, if the delta is not all around 0, it indicates that within this arm the biomarker has an association to the clinical outcome. For example, within treatment arm, suppose all high vs. low delta are greater than 0 and the delta is larger when cutting at a higher value. This indicates that among patients who received treatment, patients who have higher biomarker value tends to have better clinical outcome.

5 Biomarker subgroup analysis (using selected cutoff)


5.1 Estimations within each subgroup

The following figure shows estimate of treatment effect in biomarker subgroups, defined by the selected cutoff.

```
if(bm.class=="numeric"){
if(!is.null(numerical.finalcut)) levs <- pasteO(c(">=","<"),numerical.finalcut)
if(is.null(numerical.finalcut)) {
   nm <- quantile(input.bep[[bm]],percentile.finalcut, 2) # default quantile type in forest plot function
   numerical.finalcut <- round(nm,2) # default rounding decimal in forest plots
   levs <- pasteO(c(">=","<"),percentile.finalcut*100,"%")
}
bm2 <- pasteO(bm,"_Dx")
input[[bm2]] <- ifelse(input[[bm]] >= numerical.finalcut, levs[1],levs[2])
input[[bm2]] <- factor(input[[bm2]], levels=levs) # ">=" as Dx+
}
```

```
## Covariate adjustment and stratification are not supported for binary outcome
## Some NAs in var column, will define the non NA entries as BEP
## only 1 arm; show.itt is set to FALSE
## only 1 arm; show.bep is set to FALSE
## only 1 arm; show.bep is set to FALSE
```


Within-arm Effect of Biomarker Response, KRAS.exprs_Dx Unadjusted, unstratified analysis



5.2 Subgroup analysis

The following figure show response category distributions of the biomarker subgroups, based on selected cutoff:

```
Rsp.out <- PlotRspBar(data=input, outcome.var=outcome.var, binary=FALSE,
rsp.levels=rsp.levels, trt=trt, bep.indicator=BEP.indicator, var=bm2,
compare.var=TRUE, bep = BEP)</pre>
```



kable(Rsp.out\$count,caption="count")

Table 6: count

	CR	PR	SD	NON CR/PD	PD	NE
$\overline{\text{KRAS.exprs}}$ $Dx(>=50\%)$:All	2	48	60	24	21	0
$KRAS.exprs_Dx(<50\%):All$	3	32	62	16	40	0
All:All	5	80	122	40	61	0


kable(round(Rsp.out\$perc,2), caption="percentage")

Table 7: percentage

	CR	PR	SD	NON CR/PD	PD	NE
$\overline{KRAS.exprs}Dx(>=50\%):All$	0.01	0.31	0.39	0.15	0.14	0
$KRAS.exprs_Dx(<50\%):All$	0.02	0.21	0.41	0.10	0.26	0
All:All	0.02	0.26	0.40	0.13	0.20	0

Summarize the response in two classes - rsp vs. non-rsp:

```
Rsp.out.2 <- PlotRspBar(data=input, outcome.var=outcome.var, binary=TRUE,
rsp.response = rsp.response,
rsp.nonresponse = rsp.nonresponse,rsp.name=rsp.name, trt=trt, bep.indicator=BEP.indicator,
var=bm2, compare.var=TRUE, bep = BEP)</pre>
```



kable(Rsp.out.2\$count,caption="count")

Table 8: count

	rsp	non-rsp
$\overline{KRAS.exprs}Dx(>=50\%):All$	50	105
$KRAS.exprs_Dx(<50\%):All$	35	118
All:All	85	223

kable(round(Rsp.out.2\$perc,2), caption="percentage")

Table 9: percentage

	rsp	non-rsp
$\overline{\text{KRAS.exprs}_D x(>=50\%):All}$	0.32	0.68
$KRAS.exprs_Dx(<50\%):All$	0.23	0.77
All:All	0.28	0.72

5.3 Check whether biomarker subgroup is confounded with key clinical variables

The following table checks whether the biomarker subgroup is confounded with clinical variables. Here we check whether the clinical variable distribution is comparable in biomarker high and low group.

	$KRAS.exprs_Dx_{>}{=}50\%$	$KRAS.exprs_Dx_{<}50\%$
Sex		
Total	156	153
NA's	0	0
F	72 (46.15%)	75 (49.02%)
M	84 (53.85%)	78 (50.98%)
Age	, ,	· · · · · ·
N	156	153
Mean	53.34	55.25
Median	53	55
Min-Max	3389	3082
NA's	0	0